Simvastatin Preserves Cardiac Function in Genetically Determined Cardiomyopathy

Seena S. Abraham, Juan C. Osorio, Shunichi Homma, Jie Wang, Harshwardhan Thaker, James K. Liao, Seema Mital

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Endothelial dysfunction characterizes heart failure (HF). Simvastatin (Sim) increases endothelial nitric oxide (NO) independent of lipid-lowering. We evaluated the effect of Sim on cardiac function, apoptosis, and NO availability in HF. Five-month-old cardiomyopathic (CM) hamsters were divided into 2 groups: Sim (20 mg/kg, 6 weeks, n = 6) and Untreated (n = 6). Age-matched normal hamsters served as controls (n = 6). Serial echocardiograms were performed to measure LV function. Myocardial apoptosis, eNOS, and capillary density were measured at 6 weeks. Cardiomyopathic hamsters had lower LV shortening fraction (SF) compared with controls (17% vs 59 ± 2%), higher LV end-diastolic volume (30 ± 3 vs 6 ± 2 mL/m2), and lower LV mass/volume ratio (0.5 ± 0.04 vs 0.72 ± 0.02 mg/ml, P < 0.001). During follow-up, SF decreased (9 ± 2%) and LV volume increased (38 ± 1 mL/m2) in untreated hamsters (P < 0.05 from baseline) but did not change significantly in the Sim group (P < 0.05 vs untreated). Myocardial caspase-3 activity was higher and apoptotic nuclear density was lower in Sim compared with untreated CM hamsters (0.072 ± 0.02% vs 0.107 ± 0.03%, P < 0.01). Myocardial capillary density was highest in the Sim group (P < 0.05). eNOS expression was not different between groups. Sim retards the progression of HF in CM hamsters. This may be related to an increase in coronary microvasculature, increase in NO availability, and decreased apoptosis.

Original languageEnglish (US)
Pages (from-to)454-461
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume43
Issue number3
DOIs
StatePublished - Mar 1 2004
Externally publishedYes

Fingerprint

Simvastatin
Cardiomyopathies
Cricetinae
Nitric Oxide
Heart Failure
Apoptosis
Microvessels
Caspase 3
Lipids

Keywords

  • Angiogenesis
  • Heart failure
  • Nitric oxide
  • Remodeling
  • Statins

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Simvastatin Preserves Cardiac Function in Genetically Determined Cardiomyopathy. / Abraham, Seena S.; Osorio, Juan C.; Homma, Shunichi; Wang, Jie; Thaker, Harshwardhan; Liao, James K.; Mital, Seema.

In: Journal of Cardiovascular Pharmacology, Vol. 43, No. 3, 01.03.2004, p. 454-461.

Research output: Contribution to journalArticle

Abraham, Seena S. ; Osorio, Juan C. ; Homma, Shunichi ; Wang, Jie ; Thaker, Harshwardhan ; Liao, James K. ; Mital, Seema. / Simvastatin Preserves Cardiac Function in Genetically Determined Cardiomyopathy. In: Journal of Cardiovascular Pharmacology. 2004 ; Vol. 43, No. 3. pp. 454-461.
@article{ec5fd4f061804a27ad2670047236fc2e,
title = "Simvastatin Preserves Cardiac Function in Genetically Determined Cardiomyopathy",
abstract = "Endothelial dysfunction characterizes heart failure (HF). Simvastatin (Sim) increases endothelial nitric oxide (NO) independent of lipid-lowering. We evaluated the effect of Sim on cardiac function, apoptosis, and NO availability in HF. Five-month-old cardiomyopathic (CM) hamsters were divided into 2 groups: Sim (20 mg/kg, 6 weeks, n = 6) and Untreated (n = 6). Age-matched normal hamsters served as controls (n = 6). Serial echocardiograms were performed to measure LV function. Myocardial apoptosis, eNOS, and capillary density were measured at 6 weeks. Cardiomyopathic hamsters had lower LV shortening fraction (SF) compared with controls (17{\%} vs 59 ± 2{\%}), higher LV end-diastolic volume (30 ± 3 vs 6 ± 2 mL/m2), and lower LV mass/volume ratio (0.5 ± 0.04 vs 0.72 ± 0.02 mg/ml, P < 0.001). During follow-up, SF decreased (9 ± 2{\%}) and LV volume increased (38 ± 1 mL/m2) in untreated hamsters (P < 0.05 from baseline) but did not change significantly in the Sim group (P < 0.05 vs untreated). Myocardial caspase-3 activity was higher and apoptotic nuclear density was lower in Sim compared with untreated CM hamsters (0.072 ± 0.02{\%} vs 0.107 ± 0.03{\%}, P < 0.01). Myocardial capillary density was highest in the Sim group (P < 0.05). eNOS expression was not different between groups. Sim retards the progression of HF in CM hamsters. This may be related to an increase in coronary microvasculature, increase in NO availability, and decreased apoptosis.",
keywords = "Angiogenesis, Heart failure, Nitric oxide, Remodeling, Statins",
author = "Abraham, {Seena S.} and Osorio, {Juan C.} and Shunichi Homma and Jie Wang and Harshwardhan Thaker and Liao, {James K.} and Seema Mital",
year = "2004",
month = "3",
day = "1",
doi = "10.1097/00005344-200403000-00018",
language = "English (US)",
volume = "43",
pages = "454--461",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Simvastatin Preserves Cardiac Function in Genetically Determined Cardiomyopathy

AU - Abraham, Seena S.

AU - Osorio, Juan C.

AU - Homma, Shunichi

AU - Wang, Jie

AU - Thaker, Harshwardhan

AU - Liao, James K.

AU - Mital, Seema

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Endothelial dysfunction characterizes heart failure (HF). Simvastatin (Sim) increases endothelial nitric oxide (NO) independent of lipid-lowering. We evaluated the effect of Sim on cardiac function, apoptosis, and NO availability in HF. Five-month-old cardiomyopathic (CM) hamsters were divided into 2 groups: Sim (20 mg/kg, 6 weeks, n = 6) and Untreated (n = 6). Age-matched normal hamsters served as controls (n = 6). Serial echocardiograms were performed to measure LV function. Myocardial apoptosis, eNOS, and capillary density were measured at 6 weeks. Cardiomyopathic hamsters had lower LV shortening fraction (SF) compared with controls (17% vs 59 ± 2%), higher LV end-diastolic volume (30 ± 3 vs 6 ± 2 mL/m2), and lower LV mass/volume ratio (0.5 ± 0.04 vs 0.72 ± 0.02 mg/ml, P < 0.001). During follow-up, SF decreased (9 ± 2%) and LV volume increased (38 ± 1 mL/m2) in untreated hamsters (P < 0.05 from baseline) but did not change significantly in the Sim group (P < 0.05 vs untreated). Myocardial caspase-3 activity was higher and apoptotic nuclear density was lower in Sim compared with untreated CM hamsters (0.072 ± 0.02% vs 0.107 ± 0.03%, P < 0.01). Myocardial capillary density was highest in the Sim group (P < 0.05). eNOS expression was not different between groups. Sim retards the progression of HF in CM hamsters. This may be related to an increase in coronary microvasculature, increase in NO availability, and decreased apoptosis.

AB - Endothelial dysfunction characterizes heart failure (HF). Simvastatin (Sim) increases endothelial nitric oxide (NO) independent of lipid-lowering. We evaluated the effect of Sim on cardiac function, apoptosis, and NO availability in HF. Five-month-old cardiomyopathic (CM) hamsters were divided into 2 groups: Sim (20 mg/kg, 6 weeks, n = 6) and Untreated (n = 6). Age-matched normal hamsters served as controls (n = 6). Serial echocardiograms were performed to measure LV function. Myocardial apoptosis, eNOS, and capillary density were measured at 6 weeks. Cardiomyopathic hamsters had lower LV shortening fraction (SF) compared with controls (17% vs 59 ± 2%), higher LV end-diastolic volume (30 ± 3 vs 6 ± 2 mL/m2), and lower LV mass/volume ratio (0.5 ± 0.04 vs 0.72 ± 0.02 mg/ml, P < 0.001). During follow-up, SF decreased (9 ± 2%) and LV volume increased (38 ± 1 mL/m2) in untreated hamsters (P < 0.05 from baseline) but did not change significantly in the Sim group (P < 0.05 vs untreated). Myocardial caspase-3 activity was higher and apoptotic nuclear density was lower in Sim compared with untreated CM hamsters (0.072 ± 0.02% vs 0.107 ± 0.03%, P < 0.01). Myocardial capillary density was highest in the Sim group (P < 0.05). eNOS expression was not different between groups. Sim retards the progression of HF in CM hamsters. This may be related to an increase in coronary microvasculature, increase in NO availability, and decreased apoptosis.

KW - Angiogenesis

KW - Heart failure

KW - Nitric oxide

KW - Remodeling

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=1442276972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442276972&partnerID=8YFLogxK

U2 - 10.1097/00005344-200403000-00018

DO - 10.1097/00005344-200403000-00018

M3 - Article

VL - 43

SP - 454

EP - 461

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -